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Peripherally restricted transthyretin-based delivery
system for probes and therapeutics avoiding
opioid-related side effects
1,

Joshua S. Ho1,

1234567890():,;

Md Tariqul Haque Tuhin1,2, Dengpan Liang 1,2, Fang Liu1,2, Hala Aldawod1, Touﬁq Ul Amin
Rasha Emara1, Arjun D. Patel1, Melanie A. Felmlee1, Miki S. Park1, James A. Uchizono 1 &
Mamoun M. Alhamadsheh 1 ✉

Several investigations into the sites of action of opioid analgesics have utilized peripherally
acting mu-opioid receptor antagonists (PAMORAs), which have been incorrectly assumed to
possess limited permeability across the blood-brain barrier. Unfortunately, the poor pharmacokinetic properties of current PAMORAs have resulted in misunderstandings of the role
of central nervous system and gastrointestinal tract in precipitating side effects such as
opioid-induced constipation. Here, we develop a drug delivery approach for restricting the
passage of small molecules across the blood-brain barrier. This allows us to develop
naloxone- and oxycodone-based conjugates that display superior potency, peripheral selectivity, pharmacokinetics, and efﬁcacy in rats compared to other clinically used PAMORAs.
These probes allow us to demonstrate that the mu-opioid receptors in the central nervous
system have a fundamental role in precipitating opioid-induced constipation. Therefore, our
conjugates have immediate use as pharmacological probes and potential therapeutic agents
for treating constipation and other opioid-related side effects.
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here are several strategies for delivering therapeutics across
the blood-brain barrier (BBB)1. However, there are limited
approaches for restricting the passage of molecules across
the BBB. Such an approach would be useful for limiting the
central nervous system (CNS) toxicity of certain therapeutics with
peripheral targets (e.g., ciproﬂoxacin, methotrexate, and
indomethacin)2–4. Another application of this approach would be
to develop pharmacological probes that could be used to investigate the peripheral vs. CNS action of drug molecules such as
opioids. To limit BBB penetration, a drug molecule is typically
modiﬁed to increase its size and hydrophilicity. However, this
often adversely affects the potency and pharmacokinetic properties of the drug molecule.
Here we describe the development of an approach that limits
the undesired diffusion of molecules across the BBB. Our strategy
involves endowing the therapeutic agents with a hydrophilic
derivative of the small molecule, AG10, which binds reversibly to
the serum protein transthyretin (TTR)5. AG10 was discovered by
our group and is currently in Phase III clinical trials for TTR
amyloid cardiomyopathy (ATTR-CM)6,7. We hypothesize that
the high hydrophilicity of AG10 (AG10 exists as a zwitterion at
physiological pH) and its binding to TTR in plasma will decrease
the passive diffusion of AG10 conjugates across the BBB. In
contrast to other approaches, and through binding to TTR, our
strategy should be successful in extending the circulation half-life
of therapeutic agents without compromising their potency. We
evaluated the potential of our approach by developing pharmacological probes that provided important insights on the site of
action of opioid drugs (e.g., morphine). This information could
broaden our understanding of current clinical issues associated
with the undesirable side effects of opioids.
Opioid analgesics are effective in the management of severe
acute and chronic pain. However, they are often associated with
dose-limiting side effects, such as sedation, nausea, vomiting,
constipation, tolerance, and respiratory depression. Opioidinduced constipation (OIC) is the most common side effect of
opioid usage affecting 80% of patients who receive opioids for
cancer pain or chronic noncancer pain. OIC can be difﬁcult to
manage and, in contrast to other side effects, tolerance to OIC
does not develop8–10. OIC can be severe enough to require opioid
discontinuation, exposing the patients to unnecessary pain.
Antagonists of mu-opioid receptors, such as naloxone and naltrexone, would be useful to treat OIC. However, these drugs cross
the BBB and reverse the intended analgesic effects of opioid
agonists and often result in the precipitation of opioid withdrawal
syndrome, which can sometimes be life threatening11,12. Due to
the presence of mu-opioid receptors in the gastrointestinal (GI)
tract, it is widely assumed that OIC results primarily from the
interaction of opioids with the mu-opioid receptors in the gut.
Therefore, a main objective in pain management has been to
develop opioid antagonists that do not cross the BBB. There are
several peripherally acting mu-opioid receptor antagonists
(PAMORAs) that are clinically used to treat OIC. These drugs are
designed to have high polarity, which limits their ability to cross
the BBB, and therefore, they are not supposed to affect the
analgesic effects of opioids in the CNS. Many PAMORAs are
based on the structure of morphinan where the additional
polarity is introduced by forming a quaternary salt at the morphinan nitrogen (e.g., methylnaltrexone, which is a quaternary
derivative of naltrexone). However, the introduction of the quaternary ammonium group in opioid antagonists affects the
metabolic stability and often leads to a 100-fold reduction in
potency. For example, methylnaltrexone (MNTX) exhibits only
1% of the afﬁnity for the mu-opioid receptors as naltrexone
itself13. Another clinically used PAMORA is naloxegol, which is a
derivative of naloxone in which the tertiary amino group is
2

maintained, and a short polyethylene glycol (PEG) is introduced
at position 6 of the morphinan ring14.
It is important to note that opioid withdrawal symptoms and
an increase in pain have been reported in patients after taking
MNTX or naloxegol15,16, suggesting that these molecules or their
metabolites can cross the BBB. This observation is supported by
our data in rats (discussed below) which show that peripheral
selectivity is only maintained at low doses of these PAMORAs
that often do not produce the maximum desired reversal of OIC.
While current PAMORAs have been successful in reversing OIC
for a certain number of patients, none of the previous clinical
studies have established an improvement in quality of life in
patients taking PAMORAs8. Unfortunately, the reason for this
signiﬁcant deﬁciency with current PAMORAs has not been
addressed yet. We believe that part of this problem is due to the
poor understanding of the role of the CNS vs. GI tract in causing
constipation, which resulted from using current PAMORAs as
pharmacological probes. We show here that current PAMORAs
are poor pharmacological probes that are not suitable for performing accurate in vivo experiments. Therefore, developing a
true peripherally selective PAMORAs that do not compromise
analgesia or induce withdrawal symptoms at high doses of opioid
agonists is highly needed.
Here we show that by conjugating the opioid antagonist
naloxone to a hydrophilic derivative of AG10, we generate the
most potent and peripherally restricted PAMORA (a brief
description of the concept of our approach is shown in Fig. 1).
We report a comprehensive study of our AG10-Naloxone
PAMORA that involves chemical synthesis, in vitro binding
and stability assays, and pharmacokinetic and pharmacodynamic
evaluations in rats. The high peripheral selectivity of our AG10based PAMORA reveals insights on the important role of the
mu-opioid receptors in the CNS in causing constipation.
Importantly, our ﬁndings show that synergy or additive effect
between the mu-opioid receptors in both the CNS and GI tract is
essential for understanding OIC and how to treat it effectively.
These ﬁndings contradict reports suggesting that OIC occurred
through a mechanism involving predominantly the mu-opioid
receptors located within the GI tract17–23. We also support our
results by designing and evaluating a peripherally restricted
opioid agonist (AG10-Oxycodone conjugate) that conﬁrms the
predominant role of the CNS in precipitating OIC. Therefore, the
designed AG10-opioid conjugates represent a class of pharmacological probes that will advance our knowledge base on OIC
and other side effects. Aside from their immediate use as pharmacological probes, the designed opioid conjugates have
potential as therapeutics for OIC and other yet unexplored
therapeutic actions related to antagonizing peripherally localized
opioid activity9,24,25. This would help in developing safer and
more effective opioid therapeutics.
Results
Description of the AG10-based approach for limiting penetration across the BBB. TTR is an abundant homo-tetrameric
plasma protein (concentration ~5 μM) that is made by the liver.
TTR is also synthesized by the choroid plexus and secreted into
the cerebrospinal ﬂuid (CSF). Because of its size (55 kDa), the
circulation half-life of TTR is ~2 days26. TTR transports holoretinol binding protein from the liver to various organs26. TTR
acts as a backup carrier of thyroxine (<1% thyroxine bound)27.
The binding sites for thyroxine are orthogonal to those of holoRBP. We have recently reported a linker-modiﬁed hydrophilic
derivative of AG10, compound 1 (Fig. 2). AG10 and compound 1
bind to the two thyroxine sites in TTR and do not interfere with
the interaction between TTR and holo-RBP6,28.
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Fig. 1 Concept of the AG10-based approach to limit BBB penetration of therapeutic molecules. Lipophilic mu-opioid receptor antagonists (e.g., naloxone)
are hypothesized to reverse opioid-induced constipation (OIC) caused by the interaction of morphine (opioid agonist) with mu-opioid receptors in the
gastrointestinal (GI) tract. However, these antagonists can also cross the blood-brain barrier (BBB) and displace morphine from the mu-opioid receptors in
the brain, which results in reversing the intended analgesic effect of morphine. By conjugating naloxone to the hydrophilic derivative of AG10, we generated
an AG10-Naloxone conjugate that has limited penetration across the BBB. The high peripheral selectivity of the AG10-Naloxone conjugate to the mu-opioid
receptors in the GI tract is attributed to the high polarity of the AG10 ligand and reversible binding to the abundant plasma protein, transthyretin (TTR).
Increasing the hydrophilicity of molecules is typically associated with fast renal excretion and shorter in vivo half-life. Unlike other approaches, the binding
of our hydrophilic AG10 conjugates to TTR in plasma (TTR half-life is ~2 days) results in an extended circulation half-life. Because of their high selectivity to
the peripheral tissues, the AG10-Naloxone conjugate should reverse the action of opioid agonists (e.g., morphine) in the GI tract without compromising the
analgesic effect of opioid agonists in the brain or precipitating opioid-related withdrawal symptoms. In addition, direct intracerebroventricular
administration of the AG10-Naloxone conjugate in the brain will allow for evaluating the role of mu-opioid receptors in the brain in causing analgesia and
constipation, without any effect on mu-opioid receptors in the periphery.

We hypothesized that conjugating the opioid antagonist
(naloxone) or agonist (oxycodone) to compound 1 would limit
the BBB penetration of these opioids (Fig. 1; illustrating an
example with naloxone). The hydrophilicity of 1 would limit the
BBB penetration while binding of the AG10 portion of 1 to TTR
would increase the half-life of the naloxone and oxycodone
conjugates. Importantly, higher afﬁnity of AG10-conjugates to
mu-opioid receptors over TTR will allow the conjugate to leave
TTR and preferentially bind to mu-opioid receptors. Owing to
the reversible binding of these AG10-opioid conjugates to TTR,
the half-life of these conjugates will be enhanced, and the intrinsic
activity of the drug conjugates would not be adversely affected
(Fig. 1). Due to their high polarity, we also hypothesize that direct
intracerebroventricular administration of these conjugates in the
brain will restrict their permeation out of the CNS to the
periphery, extending their CNS action. This should provide these
probes with the ability to be concomitantly administered with
other opioids to evaluate the precise site of action for their
efﬁcacy and side effects.
Evaluation of the BBB penetration of compound 1 in rats.
Before we started with opioid antagonists and as a proof of
concept, we tested our hypothesis by evaluating the BBB penetration of compound 1 in rats. The plasma concentration of TTR
in rats (concentration ∼5 μM) is similar to that of human. Rat
TTR has high similarity with human TTR (∼80% sequence
homology at the protein levels)29,30. While there are some differences between rat and human TTR in the peripheral loop
regions, the amino acids in the two thyroxine binding sites, where
1 binds, are conserved between rat and human. Therefore, we do

not expect appreciable differences in the binding of 1 and conjugates between human or rat TTR. Compound 1 was administered intravenously (IV) through a cannula in the jugular vein.
The concentrations of 1 in plasma, brain tissue, and cerebrospinal
ﬂuid (CSF) were quantiﬁed using validated LC-MS/MS methods
(Supplementary Fig. 1 and Supplementary Table 1; calibration
curves). The plasma concentration of 1 after 30 min of the IV
bolus injection was 1.85 ± 0.34 µM. The percentage brain to
plasma ratio for 1 (1.2%) and the CSF to plasma ratio (1.3%) were
less than 2%, which clearly shows that 1 does not have signiﬁcant
penetration across the BBB (Fig. 3a). It is well established that
molecules having <2% of its plasma concentration in the brain or
CSF are not considered to cross the BBB31. These data support
our hypothesis that the hydrophilicity and selective binding to
TTR limit the ability of the AG10-conjugates to cross the BBB.
Design, synthesis, and in vitro evaluation of peripherally
restricted AG10-Naloxone conjugates. We investigated the
potential of our approach in addressing clinical issues associated
with the undesirable side effects of opioid agonists such as
morphine. We thought that naloxone (Fig. 2) would be an ideal
candidate for our approach for multiple reasons. First, naloxone
binds with high afﬁnity to the mu-opioid receptor (Ki = 0.29
nM), which is the main opioid receptor involved with OIC.
Second, the lipophilicity of naloxone allows it to rapidly cross the
BBB into the brain and achieve a greater brain-to-plasma concentration ratio. This should allow us to evaluate the effectiveness
of our approach in limiting the BBB penetration of lipophilic
molecules like naloxone. Third, the structure-activity relationship
(SAR) of naloxone is well established. It has been shown that
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Fig. 2 Chemical structures of compounds used in our studies. AG10 and compound 1 are selective TTR ligands. Naloxone is an opioid antagonist that
crosses the blood-brain barrier (BBB). MNTX and naloxegol are PAMORAs approved to treat OIC. AG10-L1-Nal and AG10-L2-Nal are conjugates of AG10
and naloxone using linkers (L1 and L2) of different lengths. Oxycodone is an analgesic opioid agonist. AG10-L2-Oxy is a conjugate of AG10 and oxycodone.

modifying position 6 of the morphinan structure does not signiﬁcantly affect the binding afﬁnity of both agonists and
antagonists such as morphine and naloxone, respectively. For
example, naloxegol is a derivative of naloxone where a hydrophilic polyethylene glycol side chain has been added at position 6
of naloxone (Fig. 2). Despite this modiﬁcation, naloxegol maintained high antagonistic potency to the mu-opioid receptors. The
well-studied SAR of naloxone strongly indicates that the binding
afﬁnity of our designed AG10-Naloxone conjugates to the muopioid receptors could be maintained. For synthesis of the AG10Naloxone conjugates, we ﬁrst conjugated an azide-modiﬁed 1
(i.e., AG10-Linker 1 or AG10-L1) to a naloxone derivative
equipped with an alkyne group at position 6 to give AG10-Linker
1-Naloxone (abbreviated as AG10-L1-Nal) (Fig. 2). AG10-L1-Nal
and all other compounds tested were >95% purity (full description of the synthesis for all conjugates and HPLC purity analysis
can be found in the Supplementary Information).
The binding afﬁnity of AG10-L1-Nal to TTR in buffer was
evaluated using ﬂuorescence polarization (FP) binding assay32
(Kd = 485.3 nM; Fig. 3b). This binding afﬁnity is lower than the
binding afﬁnity of 1 (Kd = 68.5 nM; Fig. 3b). However, this
decrease in TTR binding afﬁnity might be useful for allowing
AG10-L1-Nal to preferably leave TTR and interact with target
mu-opioid receptors. For our approach to be successful in vivo,
AG10-Naloxone conjugates should be able to selectively bind to
TTR in the presence of more than 4,000 other human serum
proteins. We evaluated the selectivity of AG10-L1-Nal binding to
TTR in human serum using a well-established TTR serum
ﬂuorescent probe exclusion (FPE) selectivity assay33,34. Our data
4

showed that AG10-L1-Nal maintained very good binding
selectivity to TTR in human serum (71.5 ± 1.8% TTR occupancy)
(Fig. 3c, d). Importantly, the performance of AG10-L1-Nal was
better than that of the TTR stabilizer, tafamidis (an approved
drug for TTR amyloidosis; 48.9 ± 2.2% TTR occupancy)35.
We then evaluated the in vitro binding afﬁnity of our test
compounds to the mu-opioid receptors (Supplementary Fig. 2
and Supplementary Table 2). The binding assay is a competitive
radioligand binding assay that measures the potency of test
compounds in displacing a radiolabeled DAMGO (a synthetic
opioid peptide with high mu-opioid receptor speciﬁcity) from
recombinant human mu-opioid receptors. The binding afﬁnity
of AG10-L1-Nal (Ki = 0.81 nM) was 3-fold lower than naloxone
(Ki = 0.29 nM) and 3.5-fold higher than naloxegol (Ki = 2.9
nM) (Supplementary Fig. 2). To mimic the conditions in vivo,
we tested the binding afﬁnity of AG10-L1-Nal to the mu-opioid
receptors in the presence of excess TTR (1 µM). Interestingly,
there was a 9-fold decrease in the binding afﬁnity of AG10-L1Nal to the mu-opioid receptors when TTR was present
(Ki = 7.4 nM). To investigate the reason behind this decrease
in binding potency, we performed a modeling study where we
evaluated the binding of AG10-L1-Nal to both TTR and the
mu-opioid receptor. It was clear that the length of the linker
between AG10 and naloxone (~20 Å) is long enough to allow
the formation of a ternary complex with both TTR and muopioid receptor (Fig. 4a). We hypothesize that this ternary
complex likely resulted in some steric hindrance from TTR that
affected the binding afﬁnity of AG10-L1-Nal to the mu-opioid
receptor.
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Fig. 3 BBB penetration study of compound 1 in rats and binding afﬁnity of 1 and AG10- conjugates (AG10-L1-Nal, AG10-L2-Nal, and AG10-L2-Oxy) to
TTR in buffer and human serum. a Percentage brain to plasma ratio and percentage CSF to plasma ratio of compound 1 in rats 30 min after intravenous
administration of compound 1 (50 µmol/kg; equivalent to 20 mg/kg). The concentration of compound 1 in plasma, brain tissue homogenate, and
cerebrospinal ﬂuid (CSF) were determined using validated LC-MS/MS methods. Bar graphs represent the respective mean (±s.d.) (n = 3 for each group).
b Binding afﬁnity of ligands to puriﬁed human TTR in buffer was evaluated using ﬂuorescence polarization assay. Compounds were tested at different
concentration (0.01 µM to 20 µM). The IC50 values were used to calculate the binding constant (Kd) using the Cheng–Prusoff equation. Data represent the
mean ± s.d. (n = 3). c Evaluation of the binding selectivity of ligands (tested at 10 μM) for TTR in human serum (concentration ~5 μM). The modiﬁcation of
TTR in human serum by covalent FPE probe was monitored for 6 h in the presence of FPE probe alone (black circles) or probe and TTR ligands (colors).
Ligands that display lower ﬂuorescence of FPE probe have higher binding selectivity to TTR. d Percent occupancy of TTR in human serum by ligands in the
presence of FPE probe. The 3 h readings, relative to probe alone, was used to calculate the percent occupancy. Error bars indicate mean ± s.d. (n = 4).
Source data are provided as a Source Data ﬁle.

To address this issue, we designed a conjugate (AG10-L2-Nal;
Fig. 2) in which the linker length was reduced to ~12 Å. The
binding afﬁnity of AG10-L2-Nal to TTR in buffer (Kd = 333 nM;
Fig. 3b) and binding selectivity to TTR in human serum
(62.5 ± 1.1%TTR occupancy) (Fig. 3c, d) were similar to that of
AG10-L1-Nal. The shorter linker of AG10-L2-Nal was sufﬁcient
to allow it to bind to either TTR or the mu-opioid receptor but
not to both at the same time (Fig. 4b, c). To test our hypothesis,
we determined the binding afﬁnity of AG10-L2-Nal to the muopioid receptors in the absence and presence of TTR. Interestingly, the binding afﬁnity of AG10-L2-Nal (Ki = 0.35 nM) was
comparable to that of naloxone (Ki = 0.29 nM) and 8.3-fold
higher than that of naloxegol (Ki = 2.9 nM). In the presence of
excess TTR (1 µM), the binding afﬁnity of AG10-L2-Nal (Ki =
1.3 nM) was 5.7-fold and 2.2-fold higher than what we observed
for AG10-L1-Nal and naloxegol, respectively (Supplementary
Fig. 2). The binding afﬁnity of AG10-L2-Nal to the mu-opioid
receptor in the presence of TTR was also 17-fold better than
MNTX (Ki = 22.1 nM)14. Therefore, it was clear that the linker
system plays an important role in the preferential binding to the

mu-opioid receptor over TTR. Because of its improved binding
afﬁnity, we decided to proceed with the biological evaluation of
AG10-L2-Nal as our lead molecule.
AG10-L2-Nal displayed competitive antagonistic activity in
mu-opioid receptor functional assays. In the [35S]GTPγS
functional binding assay, using membranes of CHO-K1 cells
stably expressing human mu-opioid receptors, AG10-L2-Nal
(20 µM) exhibited 2% agonism (mean value of 4 experiments)
relative to DAMGO (EC50 = 13.2 nM). Naloxegol displayed 6%
agonism at 20 µM. Parallel testing of AG10-L2-Nal, naloxegol,
and the potent opioid antagonist naltrexone in the mu-opioid
receptor functional assay demonstrated that AG10-L2-Nal
potency (IC50 = 7.5 nM) is similar to that of naltrexone (IC50 =
10.9 nM) and 10-fold more potent than naloxegol (IC50 = 72
nM) (Supplementary Fig. 3). These values correspond to equilibrium dissociation constant (KB) of 0.81 nM for AG10-L2-Nal
and 7.7 nM for naloxegol. The KB value for naloxegol is similar to
the reported literature value (KB = 11 nM)14. Importantly, our
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Fig. 4 Modeled complexes of AG10-L1-Nal and AG10-L2-Nal to both TTR
and mu-opioid receptors. a The linker length for AG10-L1-Nal (~20 Å) is
long enough to allow AG10-L1-Nal to bind to both the mu-opioid receptor
and transthyretin (TTR) simultaneously. The AG10-L2-Nal linker is shorter
which allows AG10-L2-Nal to bind to either b the mu-opioid receptor (pdb
id: 4DKL)55 or c TTR (pdb id: 4HIQ)6 but not both proteins at the same
time. Because of the higher afﬁnity of AG10-L2-Nal to the mu-opioid
receptor (Ki = 1.3 nM) over TTR (Kd = 333 nM), AG10-L2-Nal will
preferentially bind to the mu-opioid receptor over TTR.

functional assay data ﬁt well with the competitive binding assay
data, discussed above, where the binding afﬁnity of AG10-L2-Nal
(Ki = 0.35 nM) is 8-fold higher than that of naloxegol
(Ki = 2.9 nM).
In Schild-type experiments, AG10-L2-Nal elicited parallel
rightward shifts in the morphine dose-response curve without
any accompanying reduction in the maximal response (Emax)
produced by morphine (Supplementary Fig. 4). The EC50 of
morphine (EC50 = 0.039 µM) was increased by 950-fold in the
presence of AG10-L2-Nal (the EC50 of morphine + 0.4 µM
AG10-L2-Nal = 37.2 µM). These results demonstrate that AG10L2-Nal is a potent competitive antagonist of morphine at the
human mu-opioid receptor.
AG10-L2-Nal displayed potent activity towards other opioid
receptors. To ensure that modifying the structure of naloxone
with AG10-linker does not signiﬁcantly affect the binding to
other opioid receptors, we evaluated the binding of AG10-L2-Nal
to the delta- and kappa-opioid receptors. In comparison to both
naloxegol and MNTX, AG10-L2-Nal maintained excellent binding afﬁnity to both delta- and kappa-opioid receptors (Supplementary Figs. 5 and 6). Similar to naloxone (Ki = 12.6 nM and
2 nM for the delta- and kappa-opioid receptor, respectively),
AG10-L2-Nal binds with high afﬁnity to the delta- and kappaopioid receptors (Ki = 5.5 nM and 0.12 nM, respectively). This is
signiﬁcantly higher than naloxegol (Ki = 203 nM and 8.7 nM for
the delta- and kappa-opioid receptors, respectively) and MNTX
(Ki = 1,900 nM and 10.9 nM for delta- and kappa-opioid receptors, respectively)14.
AG10-L2-Nal does not cross the BBB in rats. Before performing
our in vivo BBB penetration and pharmacokinetic studies, we
assessed the stability of AG10-L2-Nal in mouse, rat, and human
sera (Fig. 5a and Supplementary Fig. 7). HPLC analysis showed
that AG10-L2-Nal was stable in all three sera (100% remaining)
for at least 48 h when incubated at 37 °C. For the BBB penetration
study, we compared AG10-L2-Nal to the two FDA-approved
6

opioid antagonists, naloxone (opioid antidote that readily crosses
the BBB) and naloxegol (a PAMORA approved for OIC due to its
limited BBB) (Fig. 5b, c). Test compounds were intravenously
administered to rats via a jugular vein cannula. The concentration
of test compounds in plasma, brain tissue, and CSF 30 min after
dosing was quantitated using LC-MS/MS (Supplementary Fig. 8
and Supplementary Table 1; calibration curves). The percentage
brain to plasma ratio and CSF to plasma ratios of naloxone were
~490% and 119%, respectively. These data are consistent with the
literature which showed that the concentration of naloxone is
higher in the brain and CSF than in plasma12. The brain to
plasma ratio and CSF to plasma ratio for naloxegol were 29% and
15%, respectively. The 15-29% of naloxegol that crosses the BBB
is much higher than the 2% threshold for classifying the compound’s ability to cross the BBB. While the brain and the CSF
levels of naloxegol were markedly reduced compared to naloxone,
it was surprising that signiﬁcant levels of naloxegol crossed the
BBB. In contrast, the brain to plasma ratio and CSF to plasma
ratio of AG10-L2-Nal (1.4% and 1%, respectively) were signiﬁcantly lower than naloxone. For AG10-L2-Nal, there was a 20fold decrease in brain to plasma ratio and a 15-fold decrease in
CSF to plasma ratio compared to naloxegol. This result clearly
demonstrates that AG10-L2-Nal is a highly peripherally restricted
opioid antagonist.
TTR extended the circulation half-life of AG10-L2-Nal in rats.
We have evaluated the pharmacokinetic properties of AG10-L2Nal, naloxone, and naloxegol in rats. These molecules were ﬁrst
administered as single intravenous injections (4.84 µmol/kg)
(Fig. 5d and Supplementary Table 3). Blood samples were withdrawn from the jugular vein cannula at predetermined time
points (ranging from 2 min to 24 h), and concentrations of the
test compounds were quantitated using validated LC − MS/MS
methods (Supplementary Fig. 8 and Supplementary Table 1). The
pharmacokinetic proﬁle of AG10-L2-Nal was markedly different
from naloxone and naloxegol. The plasma concentrations of
AG10-L2-Nal were higher than naloxone and naloxegol at any
given time. While there was no measurable amount of naloxone
and naloxegol 4 and 8 h after dosing, respectively, AG10-L2-Nal
was still present even after 24 h. There was a 7-fold and 3.5-fold
increase in the half-life of AG10-L2-Nal (half-life = 5.98 ± 0.81 h)
compared to naloxone and naloxegol (half-lives = 0.87 ± 0.13 h
and 1.72 ± 0.27 h, respectively). This was due to the lower clearance of AG10-L2-Nal (0.29 ± 0.02 L/h/kg), which was signiﬁcantly lower than naloxone and naloxegol (3.39 ± 0.55 L/h/kg
and 6.54 ± 0.29 L/h/kg, respectively). Importantly, the AUCinf
(exposure) of AG10-L2-Nal (16912.96 ± 1085.27 nM·h) was ∼23fold and 12-fold higher than naloxegol and naloxone
(741.34 ± 33.65 and 1455.11 ± 257.18 nM.h, respectively). These
data strongly support and validate our approach that TTR
recruitment can indeed enhance the half-life and pharmacokinetic proﬁle of AG10-L2-Nal in vivo.
For AG10-L2-Nal to have a practical clinical application, we
investigated the subcutaneous route of administration in rats.
AG10-L2-Nal, naloxone, and naloxegol were administered as
single subcutaneous doses (16 µmol/kg) (Fig. 5e, Supplementary
Fig. 8, and Supplementary Tables 1, 4). We obtained similar
pharmacokinetic proﬁles for all three compounds as observed in
the intravenous route. AG10-L2-Nal was absorbed rapidly 2 min
after subcutaneous dosing. As observed in the intravenous
administration, AG10-L2-Nal has a more favorable half-life,
clearance rate, and AUCinf compared to naloxone and naloxegol
(Supplementary Table 4). These data show that AG10-L2-Nal has
the potential to be administered using the less invasive and more
convenient subcutaneous route.
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Fig. 5 Evaluation of serum stability, BBB penetration, and intravenous/subcutaneous pharmacokinetics of AG10-L2-Nal, naloxone, and naloxegol.
a Serum stability of AG10-L2-Nal was evaluated in mouse, rat, and human sera. AG10-L2-Nal (100 μM) was incubated in sera, and the concentration
remaining in respective media was determined at 0 and 48 h using HPLC. Bar graphs represent the mean of % compound remaining ± s.d. (n = 3). b Brain
to plasma ratios and c cerebrospinal ﬂuid (CSF) to plasma ratios of AG10-L2-Nal, naloxegol, and naloxone. Male Sprague Dawley rats were dosed
intravenously with 4.84 µmol/kg of test compounds (equivalent to 1.6 mg/kg, 3.2 mg/kg, and 4 mg/kg for naloxone, naloxegol, and AG10-L2-Nal,
respectively). The plasma, brain tissue, and CSF were collected at 30 min after dosing. The ratio of the brain (ng/g) versus plasma concentration (ng/mL)
is expressed as the percentage brain to plasma ratio. The ratio of the CSF (ng/mL) versus plasma concentration (ng/mL) is expressed as the percentage
CSF to plasma ratio. Bar graphs show the respective mean (±s.d.) (n = 3 for each group). Statistical differences were determined using one-way ANOVA
followed by Tukey’s Post Hoc test (*P < 0.05 compared to naloxone). For the brain to plasma ratio experiment F(2,6) = 678.0, P < 0.0001 and for the CSF
to plasma ratio experiment F(2,6) = 174.6, P < 0.0001. d a single intravenous bolus dose of 4.84 µmol/kg and e a single subcutaneous injection of 16
µmol/kg dose of antagonists (equivalent to 5.2 mg/kg, 10.4 mg/kg, and 13.2 mg/kg for naloxone, naloxegol, and AG10-L2-Nal, respectively) were
administered to rats (n = 3 for each group). The concentration of the test compounds in plasma was determined at different time points and expressed as
means ± s.d. of three biological replicates. Source data are provided as a Source Data ﬁle.

AG10-L2-Nal does not reverse morphine-induced analgesia in
rats after intravenous administration. Our pharmacokinetic and
BBB data show that AG10-L2-Nal has a better pharmacokinetic
proﬁle and the lowest BBB penetration compared to naloxone
and naloxegol. Before investigating the potency of AG10-L2-Nal
in reversing OIC, we wanted to determine if the AG10-L2-Nal
data can be translated into less reversal of morphine-induced
analgesia. For this purpose, we used the rat hot plate model where
the degree of analgesia is evaluated by measuring the length of
time that an animal can tolerate heat from a hot plate maintained
at 55 °C. We compared the efﬁcacy of AG10-L2-Nal to two FDAapproved PAMORAs used to treat OIC (i.e., MNTX and naloxegol). We also included naloxone as an opioid antagonist with
both CNS and peripheral nervous system action.
Rats were ﬁrst dosed with saline or a single dose of morphine,
and 5 min later, the animals were given a single dose of the opioid

antagonists. In comparison to rats injected with saline (latency =
4.6 ± 1.0 seconds), rats injected with morphine (a single dose of
10 mg/kg or 35 µmol/kg) were insensitive to heat 1 h after dosing
(latency at 1 h after morphine dose = 60 seconds, which is the
maximum cutoff time to remove the animals from the hot plate)
(Fig. 6a). The morphine data is consistent with the literature
where a dose of 35 µmol/kg resulted in full analgesia. We then
tested the antagonists at doses equivalent to concomitantly
administered morphine (single doses of 35 µmol/kg). As
expected, naloxone was very effective in reversing morphineinduced analgesia (latency = 5.3 ± 0.8 seconds). Surprisingly, both
MNTX and naloxegol were also effective in fully reversing
morphine-induced analgesia (latency = 5.4 ± 1.5 seconds and
5.7 ± 1.2 seconds, respectively) (Fig. 6a). In contrast, at 35 µmol/
kg, the AG10-L2-Nal group maintained full morphine-induced
analgesia with a latency of 60 seconds. It is important to note that
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Fig. 6 Hot plate and gastrointestinal (GI) transit efﬁcacy studies of
opioid antagonists in male Sprague-Dawley rats. a Hot plate latency test
to measure analgesia. Male Sprague-Dawley rats were ﬁrst administered
with saline or a single intravenous (IV) dose of morphine (35 µmol/kg;
equivalent to 10 mg/kg). After 5 min, the morphine treated animals were
administered with a single intravenous dose of vehicle or the opioid
antagonists. Saline group: saline + vehicle; control group: 35 µmol/kg
morphine + vehicle; all other groups: 35 µmol/kg morphine + speciﬁed
dose of antagonists. The 35 µmol/kg dose of antagonists represent
11.5 mg/kg, 23 mg/kg, 12.5 mg/kg, and 30 mg/kg for naloxone, naloxegol,
methylnaltrexone (MNTX), and AG10-L2-Nal, respectively. The hot plate
withdrawal latency to heat exposure (withdrawal or shaking of the hind
paw, sharp withdrawal, licking of fore or hind paw, or attempting to escape
by jumping) was recorded 1 h after the morphine dose before the rats were
removed from the hot plate. Statistical differences were determined using
Kruskal–Wallis test followed by Dunn’s multiple comparisons test,
H = 77.02, P < 0.0001. All data are presented as mean (±s.d.) (n = 6 rats
per group, *P < 0.05). b Gastrointestinal (GI) transit assay at 1 h after
different IV bolus doses of the test compounds. The dosing schedule is
similar to the hot plate assay with an additional oral gavage of charcoal
meal 30 min after the saline or morphine dose. The signiﬁcance of
differences was measured by two-way ANOVA followed by Tukey’s post
hoc test (n = 6 rats per group, *P < 0.05), dose F(2,90) = 262.3,
P < 0.0001, compound F(5,90) = 670.8, P < 0.0001. Source data are
provided as a Source Data ﬁle.

the AG10-L2-Nal dose is ~7-fold higher than the dose we used in
the BBB study (Fig. 5b, c), which shows that our strategy is very
effective in limiting the BBB penetration of the naloxone
conjugate. To evaluate the contribution of TTR in limiting the
diffusion of AG10-L2-Nal across the BBB, we repeated the
8

analgesia experiment in the presence of the potent TTR ligand,
AG10. AG10 binds to TTR with a higher afﬁnity than AG10-L2Nal (Kd = 5 nM and 333 nM, respectively) and therefore, the
presence of saturating concentration of AG10 (dosed at 50 mg/
kg) will diminish the effect of TTR binding on the pharmacokinetic properties of AG10-L2-Nal. There was no reversal of
analgesia by AG10-L2-Nal (35 µmol/kg, equivalent to 30 mg/kg)
in the presence of AG10 (Supplementary Fig. 9a). The plasma
concentration of AG10-L2-Nal (7.6 ± 0.5 µM) was higher than the
plasma concentration of TTR (5 µM), which in addition to the
presence of AG10 in our experiment, indicate that the high
polarity of our conjugates (due to the presence of the zwitterion
in AG10) is the main driving force for limiting the passage of the
conjugates across the BBB. These data are also consistent with
data for compound 1 where even at a higher dose (50 µmol/kg;
Fig. 3a), there was no signiﬁcant BBB penetration.
Next, we tested the ability of antagonists to reverse morphineinduced analgesia at a 10-fold lower dose (3.5 µmol/kg) than
morphine. Naloxone and MNTX were effective in completely
reversing analgesia (latency = 6.2 ± 0.9 seconds and 7.1 ± 1.4 seconds,
respectively) whereas naloxegol resulted in a signiﬁcant decrease in
latency (latency = 15.5 ± 2.6 seconds) (Fig. 6a). These data agree well
with our BBB data (Fig. 5b, c), which show that a ~30% of the
naloxegol in plasma crosses the BBB at a comparable dose of 4.8
µmol/kg. Subsequently, we tested the antagonists at a 50-fold lower
dose (0.7 µmol/kg) than morphine. Naloxone resulted in signiﬁcant
reversal of analgesia (latency = 8.3 ± 1.4 seconds). At this lower dose,
there was partial reversal of morphine-induced analgesia for MNTX
(latency = 14.7 ± 2.2 seconds) and no reversal of analgesia for
naloxegol (latency = 53.8 ± 5.6 seconds) (Fig. 6a). The signiﬁcant
reversal of analgesia by MNTX has implications for patients with
advanced illnesses (e.g., incurable cancer, end-stage COPD/emphysema, cardiovascular disease, HIV/AIDS, and Alzheimer’s disease/
dementia)15 where the doses of opioid agonists needed are very
high36 and the loss of analgesia during the administration of
PAMORAs is not an option.
Evaluation of the reversal of OIC in rats after intravenous
administration of AG10-L2-Nal and antagonists. The GI transit
model was employed to determine the efﬁcacy of opioid
antagonists in reversing OIC, caused by morphine, by measuring
the distance traveled by an orally administered charcoal within
the GI tract of rats. Single doses of antagonists were administered 5 min after morphine dose (a single intravenous dose of
35 µmol/kg). In the absence of antagonists, morphine reduced
GI transit of a charcoal meal to ~15.5% of drug-free control
(Fig. 6b). Naloxone was very effective in fully restoring GI transit
and reversing OIC at all the doses tested (~96% charcoal GI
transit relative to saline group animals). At 35 µmol/kg (doses
equivalent to morphine), MNTX effectively restored full GI
transit to ~100%. Reducing the doses of MNTX by 10-fold
(3.5 µmol/kg) also resulted in signiﬁcant reversal of OIC (GI
transit = 61.6 ± 4.4%). When tested at 0.7 µmol/kg (the only
dose that showed partial hot plate analgesia, Fig. 6a), MNTX
displayed reduced charcoal movement (GI transit = 29.0 ± 6.5%)
compared to the higher doses (Fig. 6b). While naloxegol was
effective in reversing OIC at doses of 35 µmol/kg and 3.5 µmol/
kg (GI transit = 100% and 54.6 ± 6.5%, respectively), there was
no signiﬁcant reversal of OIC for naloxegol at the 0.7 µmol/kg
(a dose that resulted in no reversal of morphine-induced
analgesia, Fig. 6a, b). Interestingly, the doses of naloxegol that
were effective in reversing OIC were also effective in reversing
analgesia (Fig. 6a). These doses have been demonstrated to have
signiﬁcant CNS penetration (Fig. 5b, c). It was very surprising to
see that AG10-L2-Nal was only partially effective in reversing
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OIC at the highest dose of 35 µmol/kg (GI transit =
36.4 ± 5.4%). We investigated any potential effect of TTR
binding on the efﬁcacy of AG10-L2-Nal. There was no
improvement in the OIC in the presence of AG10 (Supplementary Fig. 9b). This is somewhat predicted since the binding
afﬁnity of AG10-L2-Nal to the mu-opioid receptor is similar in
the absence and presence of TTR (0.35 nM vs 1.3 nM) and the
plasma concentration of AG10-L2-Nal in rat efﬁcacy studies is
in the micromolar range. The data for the test compounds show
that there is a clear direct relationship between the level of
reversal of analgesia (with documented CNS site of action for
opioids) and reversal of OIC (Fig. 6a, b). Antagonists that have
higher BBB penetration (Fig. 5b, c) displayed more efﬁcient
reversal of OIC, indicating a major role of the CNS in precipitating OIC (discussed below). Our AG10-L2-Nal data also
show that we have developed what we believe is the most peripherally selective PAMORA that does not show any signiﬁcant
BBB penetration, as shown here in rats.
AG10-L2-Nal does not have partial agonistic activity to the
mu-opioid receptor. While AG10-L2-Nal effectively reverses
OIC, it was surprising that its efﬁcacy was lower than that of lower
doses of naloxone and other PAMORAs. AG10-L2-Nal is more
potent on the mu-opioid receptor and, when given at equivalent
doses, has higher concentration in the periphery (i.e., higher
plasma concentration and AUCinf) than naloxegol. Therefore, the
effect of AG10-L2-Nal should be higher on reversing OIC. The
binding afﬁnities of the antagonists used in our studies were
determined for human mu-opioid receptors, while the in vivo
efﬁcacy studies were performed in rats. However, the mu-opioid
receptors for human and rat share 94% similarity in the amino
acid sequence37 and therefore, we do not anticipate this to be a
main factor in the lower in vivo efﬁcacy of AG10-L2-Nal. To
check that the ~40% reversal of GI transit by AG10-L2-Nal was
not due to partial agonistic activity, we evaluated AG10-L2-Nal by
itself in the hot plate and GI transit tests. The goal of the hot plate
analgesia and GI transit assays was to see whether AG10-L2-Nal
showed any partial agonistic characteristics due to the structural
modiﬁcation of naloxone. In comparison to morphine, AG10-L2Nal did not display any analgesic (latency = 6.3 ± 1.3 seconds) or
OIC effects (GI transit = 98.7 ± 7.2%). These results conﬁrm our
mu-opioid receptor functional assay data (Supplementary Figs. 3
and 4) and demonstrate that AG10-L2-Nal acts as a pure
antagonist (Fig. 7a, b).
AG10-L2-Nal provides insights on the critical role of muopioid receptors in the CNS in causing OIC. The role of CNS in
precipitating OIC is not well deﬁned. The majority of studies
suggest that opioid agonists reduce GI motility through a
mechanism involving predominantly the mu-opioid receptors in
the GI tract, and this indeed is the thesis behind the development
of current PAMORAs. Our efﬁcacy data in rats (Fig. 6) indicated
that the CNS plays a major role in precipitating OIC. However, it
was not clear from our data if the mu-opioid receptors in the CNS
are directly involved in OIC. To investigate this, we performed an
experiment in which rats were administered with subcutaneous
morphine (will be distributed in the periphery and CNS) 10 min
after administering AG10-L2-Nal either directly in the brain (i.e.,
intracerebroventricular injection, ICV), subcutaneously (SC), or
both ICV + SC. Due to the high polarity of AG10-L2-Nal, ICV
administration should restrict the effect of AG10-L2-Nal to the
CNS, SC administration will only target the periphery, and
ICV + SC administration will target mu-opioid receptors in both
CNS and periphery. Our SC data were consistent with the data
observed for IV administration; there was no reversal of analgesia
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(latency = 60 seconds; Fig. 7c) and partial reversal of OIC (GI
transit = 36.0 ± 2.5% compared to 17.8 ± 2.6% for morphine)
(Fig. 7d). ICV administration of AG10-L2-Nal resulted in effective reversal of analgesia (latency = 11.1 ± 1.7 seconds) and
50.1 ± 4.2% reversal of OIC, which is higher than what we
observed for the SC route. While the ICV effect of AG10-L2-Nal
on reversing analgesia is predicted (based on the established role
of mu-opioid receptors in the CNS in causing analgesia), the OIC
results were somewhat surprising. Interestingly, concomitant
administration of AG10-L2-Nal via both ICV + SC routes
resulted in full reversal of both analgesia (latency = 3.6 ± 0.9
seconds) and OIC (GI transit = 100%) (Fig. 7c, d). These data
strongly suggest the presence of a synergistic or additive effect in
targeting mu-opioid receptors in both periphery and CNS to
induce full effect on both analgesia and OIC. While synergy was
reported for the analgesic effect of opioids38, our data also suggest
the presence of synergy or additive effect for OIC.
We next investigated if the results obtained with morphine are
applicable to other more potent mu-opioid receptor agonists. We
evaluated the ability of AG10-L2-Nal and naloxegol to reverse the
analgesia and OIC induced by fentanyl39. AG10-L2-Nal (tested at
35 µmol/kg, equivalent to 30 mg/kg) displayed similar data to
what we observed with morphine (i.e., no reversal of analgesia
and minimal reversal of OIC) (Supplementary Fig. 10). AG10-L2Nal displayed similar data even when tested at 100 mg/kg. The
data obtained for naloxegol were also consistent with the
morphine experiment. Naloxegol was effective in reversing both
analgesia and OIC induced by fentanyl (Supplementary Fig. 10).
Development of a peripherally restricted opioid agonist probe.
To conﬁrm our results above, we next investigated the role of
CNS vs. periphery in inducing analgesia and OIC using AG10Oxycodone conjugate as an agonist probe (AG10-L2-Oxy, Fig. 2).
This probe should provide direct agonistic activity without the
need for concomitant administration of morphine as we did for
the AG10-L2-Nal experiment. We decided to choose oxycodone
as the opioid agonist for our probe for two reasons. First, we
wanted to use an opioid other than morphine, which should allow
us to determine if the data we observed with morphine can be
applied to other opioid agonists. Second, oxycodone has a very
high brain-to-plasma ratio (~3-fold) compared to morphine40,41,
and therefore, it would allow us to evaluate the applicability of
our approach to limit the BBB penetration of molecules other
than naloxone. AG10-L2-Oxy demonstrated potent and selective
binding to TTR in buffer and human serum (Fig. 3b–d). In
addition, AG10-L2-Oxy demonstrated potent and selective
binding to the mu-opioid receptor (Ki = 13 nM vs. 3.1 nM for
oxycodone) compared to the delta-opioid receptor (Ki = 410 nM
vs. 958 nM for oxycodone) and kappa-opioid receptor (Ki = 120
nM vs. 677 nM for oxycodone)42.
We then evaluated the pharmacokinetic properties of AG10L2-Oxy and oxycodone after a single subcutaneous injection in
rats (Fig. 8a). The pharmacokinetic proﬁle of AG10-L2-Oxy was
markedly different from oxycodone. The concentrations of AG10L2-Oxy in plasma were higher than oxycodone at any given time.
While there was no measurable amount of oxycodone 6 h after
dosing, AG10-L2-Oxy was still present even after 24 h (detailed
pharmacokinetic parameters are shown in Supplementary Fig. 11
and Supplementary Table 1 and 5). We then evaluated the BBB
penetration of AG10-L2-Oxy in rats (Fig. 8b, c). The percentage
brain to plasma ratio and CSF to plasma ratios of oxycodone were
276% and 80%, respectively, which is consistent with the literature
data for oxycodone41,43. In contrast, there was no detectable
amounts of AG10-L2-Oxy in either brain or CSF, even at a dose
4-fold higher than that of oxycodone (Fig. 8b, c).
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Fig. 7 Evaluating the potential partial agonistic behavior of AG10-L2-Nal and contribution of mu-opioid receptors in the CNS to analgesia and OIC.
a Hot plate latency, statistical differences were determined using Kruskal–Wallis test followed by Dunn’s multiple comparisons test, H = 9.769, P = 0.0021
b and gastrointestinal (GI) transit assays to evaluate potential partial agonistic behavior of AG10-L2-Nal. Hot plate latency or GI transit were checked 1 h
after the subcutaneous dose of vehicle, morphine (35 μmol/kg), and AG10-L2-Nal (35 μmol/kg) in male Sprague-Dawley rats. Statistical differences were
determined using one-way ANOVA followed by Tukey’s post hoc test, F(2,12)=354.4, P < 0.0001 c Hot plate latency, the signiﬁcance of differences was
measured by Kruskal–Wallis test followed by Dunn’s multiple comparisons test, H = 23.23, P = 0.0001 and d GI transit assays to evaluate the contribution
of central and peripheral mu-opioid receptors to OIC. AG10-L2-Nal (35 µmol/kg; subcutaneous route, SC) and/or (0.35 µmol/kg equivalent to 88 nmol per
rat; intracerebroventricular route, ICV) or vehicle (control group) was administered at t = 0 min. Morphine (35 μmol/kg SC) or saline (saline group) was
administered at 10 min. The antagonists were administered 10 min before morphine to allow enough time to handle the animals during the ICV and SC
dosing. Charcoal was given at 40 min. Hot plate latency and GI transit were measured at 70 min. Statistical differences were determined using one-way
ANOVA followed by Tukey’s post hoc test F(4,20)=274.7, P < 0.0001. All data are presented as mean (±s.d.) (*P < 0.05, n = 5 rats per group). Source
data are provided as a Source Data ﬁle.

AG10-L2-Oxy conﬁrms the role of CNS in precipitating
analgesia and OIC. We performed an experiment in which rats
were administered with subcutaneous or intracerebroventricular
injections of oxycodone or AG10-L2-Oxy. As expected, subcutaneous administration of oxycodone (will be distributed in the
periphery and CNS) resulted in full analgesia (latency = 56.8 ± 3.8
seconds compared to 6.0 ± 0.8 seconds for vehicle) and inhibition
of GI transit (8.0 ± 2.7% compared to 100 ± 5.1% for vehicle)
(Fig. 8d, e). Subcutaneous administration of AG10-L2-Oxy resulted
10

in a minor effect on both analgesia (latency = 9.5 ± 0.8 seconds) and
GI transit (89.5 ± 3.0%). The ~10% OIC caused by the peripheral
action of AG10-L2-Oxy (Fig. 8e) is comparable to ~18% the
reversal of morphine-induced constipation we observed for AG10L2-Nal (Fig. 7d). Intracerebroventricular administration of oxycodone at a dose 4-fold higher than that of AG10-L2-Oxy did not
result in signiﬁcant analgesia or constipation. However, there was a
signiﬁcant analgesic effect (41.6 ± 4.6 seconds) and inhibition of GI
transit (18.7 ± 3.0%) at a dose 8-fold higher than that of AG10-L2-
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Fig. 8 Pharmacokinetic and pharmacodynamic evaluation of AG10-Oxycodone conjugate (AG10-L2-Oxy). a Pharmacokinetic proﬁle of AG10-L2-Oxy
and oxycodone after a single subcutaneous dose of 16 µmol/kg to rats (n = 4 per group). Plasma concentration of compounds is expressed as means ± s.d.
of three biological replicates. b Brain to plasma ratios and c cerebrospinal ﬂuid (CSF) to plasma ratios of AG10-L2-Oxy and oxycodone (n = 3 per group).
Male rats were dosed subcutaneously with 16 µmol/kg (equivalent to 5 mg/kg) oxycodone and both 16 and 64 µmol/kg AG10-L2-Oxy (equivalent to
13 mg/kg and 52 mg/kg, respectively). The plasma, brain tissue, and CSF were collected at 60 min after dosing. The ratio of the brain (ng/g) versus
plasma concentration (ng/mL) is expressed as the percentage brain to plasma ratio. The ratio of the CSF (ng/mL) versus plasma concentration (ng/mL) is
expressed as the percentage CSF to plasma ratio. Bar graphs show the respective mean (±s.d.) (n = 3 per group). Statistical differences were determined
using One Way ANOVA followed by Tukey’s post-hoc test (*P < 0.05 compared to oxycodone 16 µmol/kg group). For the brain to plasma ratio experiment
F(2,6) = 577.6, P < 0.0001 and for the CSF to plasma ratio experiment F(2,6) = 68.84, P < 0.0001. d Hot plate latency and e GI transit assays to evaluate
the contribution of opioid agonists on central and peripheral mu-opioid receptors in OIC. Oxycodone (16 µmol/kg; subcutaneous route, SC), Oxycodone
(640 and 1280 nmol per rat; intracerebroventricular route, ICV), AG10-L2-Oxy (64 µmol/kg; subcutaneous route, SC), AG10-L2-Oxy (160 nmol per rat;
intracerebroventricular route, ICV), or vehicle was administered at t = 0 min. Charcoal was given at 10 min. Hot plate latency and GI transit were measured
at 40 min. Bar graph showing the respective mean (±s.d.) (n = 5 rats per group). Statistical differences were determined using one-way ANOVA followed
by Tukey’s post-hoc test (*P < 0.05). F(5,24) = 300.5, P < 0.0001 for the hot plate assay and F(5,24) = 983.3, P < 0.0001 for the GI transit assay. Source
data are provided as a Source Data ﬁle.

Oxy. This could be a result of the higher clearance rate of oxycodone out of the brain (15-fold faster than morphine)41,44 and ﬁts
with reports that less than 2% of oxycodone remains in the brain
10 min after intracerebroventricular administration45. In contrast,
intracerebroventricular administration of an 8-fold lower dose of
AG10-L2-Oxy resulted in effective analgesia (latency = 54.2 ± 4.8
seconds) and major inhibition of GI transit (9.5 ± 2.8%). This
highlights some of the caveats of using short-acting opioids for
performing in vivo mechanistic studies and provides a clear

advantage of the longer duration of the AG10-based probes when
performing in vivo experiments.
We also evaluated the efﬁcacy of the long-acting antidiarrheal
agent loperamide in inducing constipation in our OIC rat model.
Loperamide enters the brain readily but due to efﬂux by
P-glycoprotein its CNS concentration is minimal. At therapeutic
doses, the action of loperamide is peripherally restricted to the
mu-opioid receptors in the gut. However, at higher doses
loperamide can overwhelm the efﬂux transporter, accumulate in
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the brain, and lead to opioid-related CNS adverse effects
including overdose and death46. In contrast, fentanyl (a lipophilic
drug with high CNS penetration) has a 2-fold preference for the
brain over plasma47. Similar to fentanyl, loperamide has high
potent agonist activity on the mu-opioid receptors (Ki = 0.53 nM
vs. Ki = 0.39 nM for fentanyl)48. The reported ED50 of subcutaneous loperamide for inducing constipation is 1 mg/kg (GI
transit = 50%)49. Therefore, we evaluated the efﬁcacy of
loperamide vs. fentanyl in inducing OIC at a dose of 1 mg/kg.
In our study, the inhibition of GI transit by loperamide (GI
transit = 54.5 ± 4.9%, which is consistent with literature) was 25fold lower than that of fentanyl (GI transit = 2.3 ± 1.8%)
(Supplementary Fig. 12). Increasing the dose of loperamide by 30fold (30 mg/kg) has been reported to result in less than 2-fold
decrease in GI transit (GI transit = 30%)49. It is important to note
that the anticholinergic action of loperamide (through a
nonopioid mediated process)50 may also contribute to the
inhibition of the GI transit observed in our studies.
Collectively, these data (Figs. 6–8) provide insights that
highlight the critical role of mu-opioid receptors, in both CNS
and peripheral nervous system, in causing OIC. Importantly, our
ﬁndings on the critical role of the mu-opioid receptors in the CNS
for causing OIC challenge the theory that morphine and other
opioid agonists reduce GI motility through a mechanism
involving predominantly the mu-opioid receptors in the GI tract
and that the CNS contribution to constipation is minor17–23. This
information provides clues that explain deﬁciencies associated
with current PAMORAs.
Evaluating the potential of AG10-L2-Nal as a therapeutic agent
for OIC. The data above clear some of the misunderstandings
about the mechanism of action of clinically used PAMORAs and
highlight the challenges in designing PAMORAs that provide
effective reversal of OIC while maintaining adequate levels of
analgesia. While AG10-L2-Nal displayed lower efﬁcacy than
other PAMORAs in reversing OIC, we thought that maintaining
the full analgesic effect of morphine and the extended circulation
half-life are important characteristics that warrant further evaluation of AG10-L2-Nal as a potential OIC therapeutic. To
replicate a real-life situation, we evaluated the subcutaneous route
of administration and challenged AG10-L2-Nal and naloxegol
with two doses of morphine.
There was no signiﬁcant difference between the control (2
doses of morphine) and AG10-L2-Nal (AG10-L2-Nal + 2 doses
morphine) groups in hot plate latencies (57.0 ± 2.5 and
54.7 ± 2.8 seconds, respectively) (Fig. 9a). The latency for
naloxegol (3.5 μmol/kg; the only dose that maintained some
level of analgesia, see Fig. 6) was 17.6 ± 4.0 seconds, which is
higher than that of the saline group (5.6 ± 1.3 seconds) but much
lower than that of AG10-L2-Nal and morphine groups. These
results indicate that AG10-L2-Nal does not reverse opioidinduced analgesia after 2.5 h when tested against two equimolar
doses (35 µmol/kg) of morphine (Fig. 9a). We also demonstrated
that AG10-L2-Nal signiﬁcantly reversed morphine-induced
constipation (Fig. 9b). The gastrointestinal motility for AG10L2-Nal was 49.8 ± 4.1% of the drug-free saline group, which is
signiﬁcantly higher than both naloxegol (39.7 ± 2.5%) and control
groups (15.6 ± 5.1%). The OIC reversal by AG10-L2-Nal after
2.5 h of the subcutaneous dosing is more than what we observed
at 1 h after the intravenous dose, mainly due to AG10-L2-Nal
high binding afﬁnity to opioid receptors and longer circulation
half-life.
In addition to being stable in human, rat, and mouse sera
(Fig. 5a and Supplementary Fig. 7), we found AG10-L2-Nal to be
12

chemically stable in phosphate buffer saline for at least one
month at 37 °C (Supplementary Fig. 13). Our data also showed
that AG10-L2-Nal does not interfere with TTR’s biological
function and that TTR can indeed interact with both AG10-L2Nal and holo-RBP in concert (Supplementary Fig. 14). AG10-L2Nal showed no cytotoxic effects toward two cell lines tested
(Jurkat and Hep3B cell lines; Supplementary Fig. 15). Therefore,
AG10-L2-Nal displayed excellent chemical stability, pharmacokinetics, and pharmacodynamic properties, potentially making it
an effective therapeutic candidate for treating OIC.
Discussion
For the last four decades, a growing number of investigations into
sites of action of opioid analgesics have utilized quaternary
PAMORAs, which have been assumed to have limited permeability across the BBB. On the other hand, several preclinical data
and clinical reports have indicated that these quaternary
PAMORAs, or their active parent tertiary metabolites, may
penetrate the BBB quite readily, and therefore, the results
obtained are at best difﬁcult to interpret11,15,16,51. In many of the
published reports, variables such as the type of opioid used and its
duration of action, potency, and metabolic stability11 have not
been fully considered in the design of in vivo experiments. These
variations made it difﬁcult to draw conclusions about the exact
role of the peripheral nervous system and CNS in mediating
analgesia and other side effects of opioid medications. For
example, it was suggested that morphine and other opioid agonists reduce GI motility through a mechanism involving predominantly the mu-opioid receptors in the GI tract and that the
CNS contribution to constipation is minor17–23. This was based
on experiments where OIC was fully reversed by PAMORAs
(assumed incorrectly to act only peripherally) that are concomitantly administered with morphine. We show here that the
assumption that OIC reversal is predominantly driven by
antagonism of peripheral mu-opioid receptors is incorrect. Our
drug delivery system allowed us to develop AG10-L2-Nal, which
displayed superior binding potency, peripheral selectivity, pharmacokinetics, and efﬁcacy in rats compared to other clinically
used PAMORAs. Our AG10-L2-Nal data demonstrate that the
mu-opioid receptors in the CNS, in synergy or additive effect with
the peripheral nervous system, have a fundamental role in precipitating OIC. This is supported by experiments with our AG10L2-Oxy agonist, where intracerebroventricular administration
induced substantial constipation while SC administration induced
limited constipation. Importantly, the ability to restrict our
probes either in the peripheral (by SC or IV administrations) or
central compartments (by ICV dosing) provide these molecules
with a major advantage over other opioid agonist/antagonist
probes that enter or exit the brain at variable rates (e.g., oxycodone vs. morphine), requiring these pharmacokinetic variables to
be evaluated carefully before each in vivo experiment.
In our studies in rats, it was surprising to see that a signiﬁcant
percentage of the doses of PAMORAs, currently used clinically to
treat OIC, cross the BBB. This could explain the occurrence of
opioid withdrawal symptoms and reversal of central analgesic effect
in some patients. When given concomitantly with morphine,
AG10-L2-Nal reduced constipation-related side effects while
maintaining comparable levels of analgesia to that of morphine. The
high peripheral selectivity of AG10-L2-Nal suggests that it would
not precipitate withdrawal symptoms when given with opioid
analgesics. Most of the approved PAMORAs are limited to noncancer patients, and subcutaneous MNTX is the only PAMORA
approved for OIC in cancer patients15. However, a signiﬁcant
number of patients do not respond to MNTX or experience
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Fig. 9 Hot plate and GI transit efﬁcacy studies after subcutaneous administration of AG10-L2-Nal and two doses of morphine. a Evaluation of AG10-L2Nal (single subcutaneous dose; 35 μmol/kg) and naloxegol (single subcutaneous dose; 3.5 μmol/kg) efﬁcacy in reversing analgesia, statistical differences
were determined using one-way ANOVA followed by Tukey’s post hoc test F(3,20) = 510.4, P < 0.0001 and/or b opioid-induced constipation (OIC)
caused by two subcutaneous doses of morphine (2 × 35 μmol/kg) in male Sprague-Dawley rats. The saline group received 0.9% sterile saline at 0 h,
vehicle at 5 min, and another 0.9% sterile saline dose at 1.5 h. The control group received 35 μmol/kg morphine at 0 h, followed by vehicle at 5 min, and a
second morphine dose (35 μmol/kg) at 1.5 h. All other groups received 35 μmol/kg morphine at 0 h, followed by naloxegol (3.5 μmol/kg) or AG10-L2-Nal
(35 μmol/kg) at 5 min, and a second morphine dose (35 μmol/kg) at 1.5 h. The hot plate latency was measured after 2.5 h of the ﬁrst saline or morphine
dose at 55 ± 0.5 °C temperature. For the Gastrointestinal (GI) transit assay, 1 mL of charcoal meal was given by oral gavage 30 min after the ﬁrst saline/
morphine dose. GI transit was measured after 2.5 h of the ﬁrst saline or morphine dose. Statistical differences were determined using one-way ANOVA
followed by Tukey’s post hoc test F(3,20) = 301.8, P < 0.0001. All data are presented as mean (±s.d.) (*P < 0.05, n = 6 rats per group). Source data are
provided as a Source Data ﬁle.

withdrawal symptoms. Therefore, AG10-L2-Nal has an immediate
potential use as a therapeutic agent for OIC in patients with chronic
non-cancer and chronic cancer pain where there is a need for
higher doses of opioids to obtain continuous analgesia. The bioavailability of AG10-L2-Nal via the subcutaneous route has a special
importance for cancer patients where the subcutaneous route of
administration is preferred, especially for patients with dysphagia
(i.e., swallowing difﬁculties)52.
At certain low concentrations, both naloxegol and MNTX
maintained some level of analgesia (latency ~15 seconds) and
partial reversal of OIC (GI transit = 30–50%). While this level of
efﬁcacy might be clinically effective for certain patient population,
this could also explain why some patients respond poorly to these
medications. For example, subcutaneous MNTX is the only
PAMORA approved for OIC in cancer patients15. However, a
signiﬁcant number of patients do not respond to MNTX or
experience withdrawal symptoms. By extending the half-life of
AG10-L2-Nal, we have shown that a similar or better reversal of
OIC than current PAMORAs is possible, while at the same time
maintaining full analgesia.
We believe that AG10-L2-Nal and AG10-L2-Oxy or their chemotypes offer promise as future neurochemical tools for investigating the actions of opioids and for studying the mu-opioid
receptor as a potential therapeutic target for yet unexplored applications. For example, PAMORAs have been investigated both
preclinically and clinically in counteracting the effect of opioid
agonists on promoting cancer growth and metastasis, HIV and
hepatitis C virus infection, urinary retention, postoperative ileus,
and rheumatoid arthritis progression9,24,25. Therefore, these exciting possibilities of using selective PAMORAs that do not interfere

with the intended analgesia of opioid agonists await further investigation. In summary, we have developed a drug delivery approach
for restricting the passage of small molecules across the BBB. We
demonstrated the utility of our approach by developing the most
potent and peripherally selective opioid probes. Our ﬁndings could
help in the discovery of a class of therapeutic agents or pharmacological probes, which should broaden the scope and utility of our
approach.
Methods
Evaluation of binding afﬁnity of ligands to TTR in buffer. The binding afﬁnity of
compound 1, AG10-L1-Nal, AG10-L2-Nal, and AG10-L2-Oxy to TTR in buffer
was determined by their ability to displace FP probe from TTR using a Fluorescence Polarization (FP) assay32. Serial dilutions of compound 1, AG10-L1-Nal,
AG10-L2-Nal, and AG10-L2-Oxy (0.010 µM to 20 µM) were added to a solution of
FP-probe (50 nM) and TTR (300 nM) in assay buffer (PBS pH 7.4, 0.01% TritonX100, 1% DMSO in 25 μL ﬁnal volumes) in a 384-well plate. The samples were
allowed to equilibrate by agitation on a plate shaker for 20 minutes at room
temperature. Fluorescence polarization (excitation λ 485 nm, emission λ 525 nm,
cutoff λ 515 nm) measurements were taken using a SpectraMax M5 Microplate
Reader (Molecular Devices). We used SoftMax® Pro software v5.4.1 (Molecular
Devices, Inc.) to collect the ﬂuorescence data. The IC50 values were obtained by
ﬁtting the data to the following equation [y = (A-D)/(1 + (x/C)^B) + D], where
A = maximum FP signal, B = slope, C = apparent binding constant (Kapp), and
D = minimum FP signal. The binding constant (Kd) values were calculated using
the Cheng–Prusoff equation from the IC50 values. All reported data represent the
mean ± s.d. (n = 3).
Evaluation of binding afﬁnity and selectivity of ligands to TTR in human
serum. The binding afﬁnity and selectivity of ligands compound 1, AG10-L1-Nal,
AG10-L2-Nal, and AG10-L2-Oxy to TTR in human serum was determined by
their ability to compete with the binding of a ﬂuorescent probe exclusion (FPE
probe) binding to TTR in human serum33,34. AG10 and tafamidis were used as
controls. An aliquot (98 µL) of human serum was mixed with 1 μL of test
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compounds (1.0 mM stock solution in DMSO; 10 µM ﬁnal concentration in serum)
and 1 μL of FPE probe (0.36 mM stock solution in DMSO; 3.6 µM ﬁnal concentration in serum). The ﬂuorescence changes (λex = 328 nm and λem = 384 nm)
were monitored every 15 min using a SpectraMax M5 microplate reader for 6 h
at 25 °C.
Evaluation of the brain uptake of the experimental compounds in rats. Jugular
vein cannulated male Sprague Dawley rats were used for this study. Animals were
randomized in various treatment groups (n = 3 animals per group). Each animal
received one 50 µmol/kg intravenous bolus dose of compound 1 or 4.84 µmol/kg
dose of naloxone, naloxegol, or AG10-L2-Nal in 200 µL dosing solution, followed
by an injection of 200 µL sterile saline to ﬂush the jugular vein cannula. Oxycodone
(16 µmol/kg) and AG10-L2-Oxy (16 & 64 µmol/kg) doses were administered
subcutaneously. The doing solution (vehicle) was composed of 10% DMSO, 20%
PEG400 and 70% sterile deionized water. 30 min (for compound 1, naloxone,
naloxegol and AG10-L2-Nal) or 60 min (for oxycodone and AG10-L2-Oxy) after
the dosing, the rats were anesthetized with an intraperitoneal injection of 90 mg/kg
ketamine and 9 mg/kg xylazine. The CSF samples were collected from the cisterna
magna with a 22-gauge needle. The blood was collected from the aortic exsanguination with a 20-gauge needle followed by decapitation and brain collection.
The brain was immediately snap frozen in the liquid nitrogen.
Evaluation of the intravenous and subcutaneous pharmacokinetic proﬁle of
naloxone, naloxegol, and AG10-L2-Nal in rats. Jugular vein cannulated male
Sprague Dawley rats (225–250 g; 7-8 weeks old) from Charles River were used for
both intravenous (IV) and subcutaneous (SC) pharmacokinetic (PK) studies. For
the IV PK study, each animal received one intravenous bolus dose of either
naloxone, naloxegol, or AG10-L2-Nal (4.84 µmol/kg) in 200 µL dosing solution
followed by an injection of 200 µL sterile saline to ﬂush the jugular vein cannula
(n = 3 rats per group). 200 µL blood samples were collected from each rat, via
jugular vein cannula, in heparinized tubes at predetermined time points (0.033, 0.5,
1, 2, 4, 6, 8, 12, and 24 h postdosing), and the volume was replaced with sterile
normal saline. For the SC PK study, each animal received one subcutaneous 16
µmol/kg dose of either naloxone, naloxegol, or AG10-L2-Nal, in 500 µL dosing
solution (per 250 g rat) in the scruff area. Blood samples were collected from each
rat via jugular vein cannula, in heparinized tubes at predetermined time points
(0.033, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, and 24 h postdosing), and the same volume
was replaced with sterile normal saline. For the oxycodone and AG10-L2-Oxy SC
PK study, 500 µL dosing solution was administered (per 250 g rat) in the scruff area
and blood samples were collected at 0.033, 0.5, 0.75, 1, 2, 4, 6, 8, 12, and 24 h. The
blood samples were prepared the same way as described in the brain uptake study.
LC-MS/MS analysis and sample preparation. The plasma analysis of naloxone,
naloxegol, AG10-L2-Nal, oxycodone, and AG10-L2-Oxy were performed the same
way as the plasma samples from the brain uptake study of these molecules. A noncompartmental analysis model using Phoenix WinNonlin (version 8) was used to
obtain all the intravenous and subcutaneous pharmacokinetic parameters from
their plasma concentration−time data.
Hot plate analgesia assays. Hot plate analgesia meter from Columbus Instruments, Ohio, USA was used for the experiment. The hot plate was maintained at
55 ± 0.5 °C. The maximum length of hot plate exposure was set at 60 seconds to
avoid any kind of tissue damage. The withdrawal latency to heat exposure (withdrawal or shaking of the hind paw, sharp withdrawal, licking of fore or hind paw,
or attempting to escape by jumping) was recorded and the animal was gently and
quickly removed from the hot plate. A footswitch connected to the analgesia meter
was used to control the timer. Experimenters were blinded to treatment groups.
Pre-dose control response was measured before dosing to establish baseline
withdrawal latencies. Predose baseline latencies were ranked, and the animals were
allocated to treatment groups, so the mean baseline latencies were similar among
groups. The day before the experiment, the rats were placed on the hot plate at
normal ambient temperature for half an hour to let them get accustomed to the
instrument. The temperature in the experimental room was 22 ± 2 °C. Relative
humidity was not controlled in the experiment room while performing the
experiment. The rats went through a short fasting (8–12 h) when there was no
reported corticosterone hormone level ﬂuctuation, to minimize the stress associated with fasting during these behavior experiments.
Gastrointestinal (GI) transit assays. The well-established rat GI transit model
was employed to determine the ability of opioid antagonists to antagonize
morphine-induced constipation by measuring the distance traveled by a charcoal
within the GI tract of the fasted male SD rats. Rats were fasted for a short period of
time (8–12 h) to minimize the stress associated with fasting during the
experiment53,54. The charcoal meal was prepared by 10% w/v charcoal and 10% w/
v gum Arabic in tap water.

standard deviation (s.d.). A priori analysis revealed that to achieve a statistical
power of 0.8 with alpha equal to 0.05, given our experimental s.d. values, the
number of animals per group must be more than 2. The power analysis was
performed by G*Power software (version 3.0.10). For data meeting normality tests
using the Shapiro-Wilk test, statistical difference was determined using parametric
tests (two-tailed unpaired t-test with equal variance or one-way/two-way ANOVA
followed by Tukey’s multiple comparison test). For nonparametric data, statistical
differences were determined using the Kruskal-Wallis test followed by Dunn’s
multiple comparisons test to identify which groups showed statistical difference.
All statistical analyses were indicated in the ﬁgure legends or in the tables. Signiﬁcant differences were determined at (*) P < 0.05.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
The authors declare that all the data supporting the ﬁndings of this study are available
within the article and Supplementary Information ﬁles. The publicly available protein
structures can be found in pdb id: 4HIQ and 4DKL. All compounds (including AG10-L1Nal, AG10-L2-Nal, and AG10-L2-Oxy) can be obtained through a standard material
transfer agreement by contacting malhamadsheh@paciﬁc.edu. Source data are provided
with this paper.
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